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A B S T R A C T
Purpose: Pentylenetetrazole and maximal electroshock rodent seizure models are commonly used to
detect antiepileptic efﬁcacy in drug development. The aim of this research was to evaluate the predictive
capabilities of pentylenetetrazole and maximal electroshock models in estimating human exposures
required for antiepileptic efﬁcacy through a survey of current literature.
Methods: A literature search was undertaken to identify articles describing pentylenetetrazole or
maximal electroshock models in rat or mice, where at least one of nine pre-selected antiepileptic drugs
based on evidence of efﬁcacy were used. Exposures at the median doses of the approved human dose
range for these drugs were compared to exposures at doses that inhibit maximal response by 50%
(ED50s) from the pentylenetetrazole and maximal electroshock models. Ratios of the human to rodent
exposures were calculated and summarised statistically and graphically.
Results: Across the nine antiepileptic drugs investigated, the average (standard deviation) ratio of
exposures comparing the median human efﬁcacious dose to mice ED50 dose was 1.4 (3.9) for the
pentylenetetrazole model and 3.8 (3.1) for the maximal electroshock model. In the rat, ratios in the
maximal electroshock and pentylenetetrazole model were 4.1 (2.1) and a range of 1–2, respectively.
Conclusion: Based on the nine antiepileptic drugs investigated, the pentylenetetrazole model appeared
to predict human exposures more accurately than the maximal electroshock model. There did not appear
to be differences between rat and mice in either of the seizure models, therefore both species could be
used equally. Both the pentylenetetrazole and maximal electroshock models are useful tools in screening
compounds in early drug discovery.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
In the discovery phase of drug development, in vivo pharma-
cology experiments in animals are commonly used alongside in
vitro experiments to screen for efﬁcacy and early detection of
activity. In the area of epilepsy, several nonclinical pharmacology
models are available, which generally involve the application of aAbbreviations: AED, antiepileptic drug; AUC, area under the plasma concentration
vs time curve; CBZ, carbamazepine; ED50, dose that inhibits maximal response by
50%; FDA, Food and Drug Administration; GBP, gabapentin; ILAE, International
League against Epilepsy; LTG, lamotrigine; MED, median effective dose; MES,
maximal electroshock; NIH, National Institutes of Health; OXC, oxcarbazepine; PB,
phenobarbital; PHT, phenytoin; PTZ, pentylenetetrazole; TPM, topiramate; VGB,
vigabatrin; VPA, valproate.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rechemical or electrical stimulus to invoke seizures in rodents. The
ability of an investigative drug to prevent these seizures is then
observed. In an effort to facilitate the discovery of new anti-
epilepsy drugs (AEDs), the National Institutes of Health (NIH) runs
an anticonvulsant screening program,1 where submitted potential
anticonvulsants undergo a list of screening tests in various animal
seizure models.
Two commonly used in vivo nonclinical pharmacology seizure
models in the NIH program – the pentylenetetrazole seizure (PTZ)
model and the maximal electroshock seizure (MES) model – have
been in use for decades and are currently still in use. In the PTZ
model, the convulsant chemical pentylenetetrazole is injected
subcutaneously into the rodent to produce clonic seizures. The
ability of a test compound at different pretreatment doses/times to
raise the seizure threshold and protect the animal from exhibiting
a clonic seizure is observed, usually for 30 min after injection of
PTZ. With the MES seizure model, an alternating current is
delivered through corneal electrodes to induce a seizure in rodents.served.
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doses/times to prevent the spread of seizure discharge and protect
the animal from exhibiting hindlimb tonic seizures is observed.
PTZ models are often associated with absence seizures whilst MES
models are associated with general tonic-clonic seizures. In both
models, a dose that inhibits maximal response by 50% (ED50) is
often calculated from these experiments.
We have previously shown that photosensitive proof of
principle trials in human can predict human antiepileptic efﬁcacy,2
and therefore can be a useful tool in drug development. Prior to
ﬁrst human dose testing, data from animal pharmacology models
already available can potentially be used to inform and predict
exposures in humans required for efﬁcacy. The aim of this research
was to evaluate whether preclinical seizure models – speciﬁcally
the PTZ and MES rodent models – can be early predictors of human
exposures required for antiepileptic efﬁcacy. This was performed
through a survey of current literature reporting ED50 results from
commonly prescribed AEDs.
2. Materials and methods
In order to streamline the list of AEDs, only those that presented
with good evidence of efﬁcacy were selected according to the
International League Against Epilepsy (ILAE) treatment guide-
lines.3 Drugs with the highest levels of evidence for efﬁcacy
included carbamazepine (CBZ), phenytoin (PHT), valproate (VPA),
gabapentin (GBP), lamotrigine (LTG), oxcarbazepine (OXC), phe-
nobarbital (PB), topiramate (TPM) and vigabatrin (VGB). A
literature search was then undertaken in Medline using key words
of ‘‘PTZ seizure’’ or ‘‘MES seizure’’, ‘‘mice’’ or ‘‘rat’’ and the
respective drug name. Articles in English published before
December 2012 describing an ED50 value with single dose
treatment with any of the AEDs listed above in a PTZ or MES
model were included. The average value of the rodent ED50s
obtained from the various literature sources was then calculated.
The range and median effective doses (MEDs) in humans for the
nine drugs listed above in the treatment of epilepsy were obtained
from the individual Food and Drug Administration (FDA) approved
drug labels. In order to account for species differences inTable 1
Average ED50 values from mice and rat PTZ and MES models across articles gathered 
AED Mice 
No. of articles reporting ED50 Average ED50 (mg/kg) CV (%)
PTZ model
CBZ 14 NEb NE 
GBP 6 168 56 
LTG 4 9.11a 30 
OXC 2 22.8 12 
PB 25 14.6 66 
PHT 18 NEc NE 
TPM 4 526a 135 
VGB 4 607a 3 
VPA 37 199 76 
MES model
CBZ 48 11.2 44 
GBP 4 105 23 
LTG 22 5.26 28 
OXC 13 10.8 9 
PB 45 20.3 29 
PHT 52 8.71 28 
TPM 20 42.9 24 
VGB 3 NE NE 
VPA 54 263 37 
NE, not efﬁcacious; CV, coefﬁcient of variation. Some articles report ED50 values for m
a 50% of articles reported AED as not efﬁcacious.
b 71% of articles reported AED as not efﬁcacious.
c 89% of articles reported AED as not efﬁcacious.disposition of the AEDs between rodents and humans, doses were
converted to exposures for comparison. Exposures expressed as
area under the plasma concentration time curve (AUC) for human
MED and rodent ED50 were calculated using the following
equation:
AUC ¼ Dose ðhuman MED or rodent ED50Þ
CL
The human and rodent plasma clearance (CL) values for each
AED were obtained from the FDA approved drug labels, FDA
reviews, or literature.4–12 Since mice pharmacokinetics were not
commonly reported, mouse clearance where unavailable was
scaled down from rat clearance using simple allometry principles
with the following equation:
CLmouse ¼ CLrat  Weightmouse
Weightrat
 0:75
The standard weights used for the allometric scaling calcula-
tions for mice, rat and human were 0.025, 0.25 and 70 kg,
respectively. Ratios of AUC at human MED to AUC at rodent ED50
were calculated. These ratios were described by summary statistics
and exposure comparisons were summarised graphically.
3. Results
A total of 1274 articles were identiﬁed in the literature search
across different combinations of search terms as described in the
methods section. Of these, 27 articles were found to contain
information on ED50 in PTZ models,13–39 67 in MES models,40–106
and 27 in both models.107–133
Table 1 shows the mean and variability of the ED50s in mice
and rat PTZ and MES models reported across the various literature
papers for the nine AEDs investigated. Generally, there were fewer
articles describing experiments in rats compared to mice, and
more articles were found describing MES than PTZ models. ED50
values for the PTZ model ranged from approximately 10 mg/kg to
600 mg/kg across the nine AEDs investigated, and PHT and CBZ
were not effective in this model. In the MES model, the ED50 valuesfrom literature survey.
Rat
 No. of articles reporting ED50 Average ED50 (mg/kg) CV (%)
4 NE NE
0 – –
1 NE NE
0 – –
7 23.4 61
9 NE NE
1 NE NE
0 – –
10 551 157
12 9.64 108
1 15.0 –
3 2.80 75
0 – –
13 12.6 74
19 39.0 115
2 9.55 93
0 – –
19 399 34
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Fig. 1. AUC exposures at human MED and approved dose ranges and at ED50 in the
mice and rat PTZ and MES models for different AEDs.
Table 2
Ratio of AUCs at human MED vs AUC at rodent ED50 for each antiepileptic drug in the PTZ and MES models.
AED PTZ model MES model
Human:mice Human:rat Human:mice Human:rat
CBZ NE NE 27 18
GBP 0.6 – 1.0 4.7
LTG 1.2 NE 2.1 2.2
OXC 7.5 – 16 –
PB 3.7 1.0 2.7 1.8
PHT NE NE 3.5 5.0
TPM 0.2 NE 1.9 4.6
VGB 0.8 – NE –
VPA 4.3 2.0 3.2 2.8
Geometric mean (SD) 1.4 (3.9) 1.0–2.0a 3.8 (3.1) 4.1 (2.1)
Geometric mean without CBZ and OXC (SD) 1.2 (3.5) – 2.2 (1.7) 3.3 (1.8)
NE, not efﬁcacious; SD, standard deviation.
a Data shown as range.
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400 mg/kg. Of the nine AEDs investigated, all except VGB were
effective in this model. There was larger variability in ED50s in the
PTZ model, especially with CBZ, LTG, PHT, TPM and VGB, where
some studies reported ED50 doses whilst others stated that there
was no efﬁcacy in this model across a wide dose range tested.
Consequently, ED50 values were only shown in Table 1 when at
least 50% of the articles found for that particular AED reported an
ED50 value.
The comparison of AUC ratios at human MED to rodent ED50 are
shown in Table 2. The results show that across the nine AEDs
investigated, the average [standard deviation (sd)] ratio of
exposures at human MED to mice ED50 was 1.4 (3.9) for the
PTZ model and 3.8 (3.1) for the MES model. There was less
information available in rats compared to mice, but ratios were
similar with a range of 1–2 for rat in the PTZ model and average
(sd) of 4.1 (2.1) in the MES model. CBZ and OXC appeared to be
outliers, therefore summary statistics were also calculated without
these two AEDs. Comparison of human exposures at MED and
rodent exposures at ED50 in the PTZ and MES models across the
various AEDs are summarised graphically in Fig. 1.
4. Discussion
This literature survey investigated whether PTZ and MES rodent
seizure models can quantitatively predict human exposures
efﬁcacious in epilepsy, by comparing the exposure in human
efﬁcacious doses versus the exposures at ED50 in the rodent PTZ
and MES models. The results showed that the ratios of human
exposures at MEDs to rodent exposures at ED50 in both PTZ and
MES models were close to 1 (mean of approximately 1.5 and 4 for
PTZ and MES, respectively). Thus, both these rodent seizure models
can be useful tools in early drug development.
The PTZ model performed slightly better than the MES model
with a ratio closer to 1 and with a mixture of over and under-
predictions across the nine AEDs selected. The MES model, on the
other hand, tended to consistently under-predict human expo-
sures/doses required for efﬁcacy, resulting in mean ratios of
approximately 4 for both mice and rat. This consistent under-
prediction could be due to the way the experiments were
conducted, where ED50s were obtained at a single time point
when peak effect of the particular AED was observed. In humans,
although peak effect is important, maintaining efﬁcacy over the
entire dosing interval is equally important to prevent any
breakthrough seizures when AED concentrations are at trough
levels. Thus, it is also important to conduct time course
experiments in rodents to obtain ED50s when AED concentrations
are lower, and to observe if there are any delays between peak
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netic/pharmacodynamic modelling techniques can often be useful
in these instances, with various examples already found in
literature including the modelling of anticonvulsant action of
phenobarbital in rats134 and the correlation of various AEDs in the
cortical stimulation model.135 These models can be used to provide
a more robust and conservative estimate of human efﬁcacious
exposures and/or doses.
The PTZ and MES models seemed to perform equally well
across drugs with different mechanisms of action. Of the nine
drugs investigated, four potentiate gamma-aminobutyric acid
(GABA) inhibition (GBP, PB, VB and VPA), four modulate voltage-
dependent sodium/calcium channels (CBZ, LTG, OXC and PHT) and
TPM has mixed mechanisms. The ratios of human MED to rodent
ED50 exposures did not appear to be different across all these
compounds with different mechanisms of action, with the
exception of CBZ and OXC, which showed the highest ratios.
The reasons for these ﬁndings are unknown, however it is
interesting that CBZ and OXC are related analogues. Further
investigation into exposure ratios for Eslicarbazepine, another
related analogue to CBZ, may help resolve this trend. Neverthe-
less, it is encouraging that the PTZ and MES models show efﬁcacy
and predictability into humans across AEDs with different
mechanisms of actions.
False negatives were present in both rodent models, with PHT
and CBZ not showing efﬁcacy in the PTZ model but good efﬁcacy in
the MES model. There tended to be fewer false negatives in the MES
model with only VGB not showing efﬁcacy in the MES model but
efﬁcacy in the PTZ model. Given these false negatives, potential
antiepileptic compounds should not be screened solely against one
single model but to be tested across a few different seizure models.
This literature survey pre-selected efﬁcacious human AEDs, thus it
would not have captured true negative cases or false positive cases
in using the PTZ or MES models to predict human efﬁcacy.
Although the AUC ratio was closer to 1 for the PTZ model, the
higher AUC ratio for the MES model was associated with lower
variability, and therefore if a correction factor (of approximately 4)
was applied, human dose predictions with better precision could
be obtained with the MES model instead. However these analyses
were done with only nine AEDs and more AEDs should be added in
order for a more robust correction factor to be calculated and used.
Besides, the aim of early human dose predictions is to evaluate the
feasibility of dosing up to predicted efﬁcacious doses in humans in
a safe manner consistent with known toxicology data. In practice, a
wide range of human doses will be explored in Phase 1 clinical
trials beyond these predicted efﬁcacious doses, which make the
precision of the predicted dose less important than its mean value
at this stage of drug development. A general recommendation from
these analyses could be to use the MES model in efﬁcacy screening
for compound prioritisation since there have been fewer false
negatives with this method, but to use the PTZ model for human
dose prediction calculations (along with acknowledgement of the
uncertainty involved). Although there was generally no difference
between rat and mice AUC ratios in each seizure model, more data
was available for mice compared to rat and therefore whilst both
species could be used equally, caution should be used when
interpreting data from rats. If comparisons against values in
literature were to be made, then more information is available in
mice.
In conclusion, both the rodent PTZ and MES seizure models can
reasonably predict human efﬁcacious doses and exposures in
epilepsy, and could be used as tools in screening and prioritisation
of compounds in early drug discovery. Early accurate predictions of
human efﬁcacious doses (together with all the other information
generated at the preclinical stage), allow better risk/beneﬁt
assessment of whether to carry forward the compound into thenext stage of development, which is invariably more costly and
time consuming.
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